Revelation Biosciences, Inc. (REVBW) shareholders
REVBWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVB
$0.01+0.00 (0.00%)
Close on Oct 30, 2026Market cap $16.05MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1M
Shares held, 13F filers
Institutional holders
13
2 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sabby Management, LLC Joint filing with Hal Mintz (9.60%), Sabby Volatility Warrant Master Fund, Ltd. (9.60%) | 605,702 | 9.60% | 13G (passive) | Dec 31, 2025 |
| Armistice Capital, LLC Joint filing with Steven Boyd (7.80%) | 323,241 | 7.80% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of REVBW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Linden Advisors LP | 337,752 | – | $2.40K | −358 | 0.00% |
| Clear Street Group Inc. | 246,934 | – | $1.95K | −600 | 0.00% |
| Pine Valley Investments Ltd Liability Co | 236,857 | – | $1.87K | −8,572 | 0.00% |
| T3 Companies, LLC | 198,090 | – | $1.57K | – | 0.00% |
| Toronto Dominion Bank | 99,050 | – | $792 | −500 | 0.00% |
| Wolverine Asset Management LLC | 54,752 | – | $433 | – | 0.00% |
| Virtu Financial LLC | 50,463 | – | $0 | New | 0.00% |
| Jane Street Group, LLC | 50,000 | – | $395 | – | 0.00% |
| Susquehanna International Group, Llp | 42,266 | – | $262 | New | 0.00% |
| Soltis Investment Advisors LLC | 22,500 | – | $178 | −25,000 | 0.00% |
| Citadel Advisors LLC | 18,716 | – | $116 | −13,684 | 0.00% |
| UBS Group AG | 3,532 | – | $28 | +3,000 | 0.00% |
| Quaker Wealth Management, LLC | 387 | – | $4 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 1M | 2 / 1 | 6 / 0 | 0M | 0M |
| Q1 2026 | 11 | 1M | 1 / 3 | 0 / 1 | 0M | 0M |
| Q4 2025 | 11 | 1M | 1 / 1 | 1 / 1 | 0M | 0M |
| Q3 2025 | 11 | 1M | 1 / 0 | 3 / 1 | 0M | 0M |
| Q2 2025 | 12 | 1M | 5 / 1 | 1 / 2 | 0M | 0M |
| Q1 2025 | 9 | 1M | 1 / 1 | 2 / 3 | 0M | 0M |
| Q4 2024 | 11 | 1M | 0 / 2 | 5 / 2 | 0M | 0M |
| Q3 2024 | 13 | 1M | 1 / 0 | 5 / 2 | 0M | 0M |
| Q2 2024 | 14 | 1M | 3 / 1 | 2 / 1 | 0M | 0M |
| Q1 2024 | 12 | 1M | 0 / 1 | 3 / 0 | 0M | 1M |
| Q4 2023 | 12 | 2M | 1 / 11 | 0 / 2 | 2M | 0M |
| Q3 2023 | 14 | 0M | 2 / 3 | 1 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| James Rolke | Chief Executive Officer, Director | 424,958 | Aug 18, 2026 |
| Chester Stanley Zygmont III | Chief Financial Officer | 508,211 | Aug 18, 2026 |
| Lakhmir S. Chawla | Director | 44,169 | Aug 18, 2026 |
| Jennifer Carver | Director | 44,769 | Aug 18, 2026 |
| Jess Roper | Director | 44,839 | Aug 18, 2026 |
| George F. Tidmarsh | Director | 268 | Feb 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James Rolke Chief Executive Officer, Director | Aug 17, 2026 | Award | +208,076 | – | – | 422,814 |
| Jess Roper Director | Aug 17, 2026 | Award | +32,011 | – | – | 44,839 |
| Chester Stanley Zygmont III Chief Financial Officer | Aug 17, 2026 | Award | +208,073 | – | – | 208,073 |
| Chester Stanley Zygmont III Chief Financial Officer | Aug 17, 2026 | Gift | +208,073 | – | – | 300,136 |
| Chester Stanley Zygmont III Chief Financial Officer | Aug 17, 2026 | Gift | −208,073 | – | – | 0 |
| Jennifer Carver Director | Aug 17, 2026 | Award | +32,011 | – | – | 44,769 |
| Lakhmir S. Chawla Director | Aug 17, 2026 | Award | +32,011 | – | – | 44,169 |
| Chester Stanley Zygmont III Chief Financial Officer | Apr 30, 2026 | Tax withholding | −13,285 | $1.10 | $14.61K | 92,063 |
| James Rolke Chief Executive Officer, Director | Apr 30, 2026 | Tax withholding | −10,115 | $1.13 | $11.43K | 214,738 |
| Chester Stanley Zygmont III Chief Financial Officer | Feb 4, 2026 | Tax withholding | −13,100 | $1.65 | $21.62K | 105,348 |
| Jess Roper Director | Feb 3, 2026 | Tax withholding | −1,591 | $1.85 | $2.94K | 12,828 |
| Lakhmir S. Chawla Director | Feb 3, 2026 | Tax withholding | −2,261 | $1.85 | $4.18K | 12,158 |
| Jennifer Carver Director | Feb 3, 2026 | Tax withholding | −1,661 | $1.87 | $3.11K | 12,758 |
| James Rolke Chief Executive Officer, Director | Feb 3, 2026 | Tax withholding | −8,521 | $1.86 | $15.85K | 224,853 |
| Jennifer Carver Director | Jan 8, 2026 | Award | +41,981 | $0.90 | $37.78K | 57,669 |
| Lakhmir S. Chawla Director | Jan 8, 2026 | Award | +41,981 | $0.90 | $37.78K | 57,667 |
| James Rolke Chief Executive Officer, Director | Jan 8, 2026 | Award | +532,829 | $0.90 | $479.55K | 933,489 |
| Chester Stanley Zygmont III Chief Financial Officer | Jan 8, 2026 | Award | +78,145 | $0.90 | $70.33K | 473,790 |
| Jess Roper Director | Jan 8, 2026 | Award | +41,981 | $0.90 | $37.78K | 57,667 |
| James Rolke Chief Executive Officer, Director | Oct 29, 2025 | Award | +390,614 | $1.28 | $499.99K | 400,660 |
| Chester Stanley Zygmont III Chief Financial Officer | Oct 29, 2025 | Award | +390,614 | $1.28 | $499.99K | 395,645 |
| Jennifer Carver Director | Oct 29, 2025 | Award | +15,625 | $1.28 | $20.00K | 15,688 |
| Jess Roper Director | Oct 29, 2025 | Award | +15,625 | $1.28 | $20.00K | 15,686 |
| Lakhmir S. Chawla Director | Oct 29, 2025 | Award | +15,625 | $1.28 | $20.00K | 15,686 |
| Jennifer Carver Director | Feb 11, 2025 | Award | +181 | $3.87 | $700 | 187 |
| James Rolke Chief Executive Officer, Director | Feb 11, 2025 | Award | +30,095 | $3.87 | $116.47K | 30,137 |
| Chester Stanley Zygmont III Chief Financial Officer | Feb 11, 2025 | Award | +15,048 | $3.87 | $58.24K | 15,076 |
| Jess Roper Director | Feb 11, 2025 | Award | +181 | $3.87 | $700 | 183 |
| Lakhmir S. Chawla Director | Feb 11, 2025 | Award | +181 | $3.87 | $700 | 181 |
| George F. Tidmarsh Director | Feb 11, 2025 | Award | +181 | $3.87 | $700 | 268 |
| George F. Tidmarsh Director | Dec 8, 2023 | Sale | −27,771 | $0.52 | $14.44K | 0 |
| George F. Tidmarsh Director | Oct 16, 2023 | Sale | −1,845 | $0.65 | $1.20K | 27,771 |
| George F. Tidmarsh Director | Oct 16, 2023 | Sale | −10,957 | $0.66 | $7.23K | 42,096 |
| George F. Tidmarsh Director | Sep 28, 2023 | Sale | −1,429 | $0.69 | $986 | 42,096 |
| George F. Tidmarsh Director | Sep 18, 2023 | Sale | −4,000 | $0.74 | $2.96K | 39,348 |
| George F. Tidmarsh Director | Sep 15, 2023 | Sale | −9,500 | $0.73 | $6.94K | 43,348 |
| George F. Tidmarsh Director | Sep 14, 2023 | Sale | −12,000 | $0.75 | $9.00K | 52,848 |
| George F. Tidmarsh Director | Apr 18, 2023 | Buy | +25,000 | $1.16 | $29.00K | 64,848 |
| George F. Tidmarsh Director | Apr 17, 2023 | Buy | +26,500 | $1.16 | $30.74K | 39,848 |
| George F. Tidmarsh Director, 10% owner | Feb 25, 2022 | Buy | +20,000 | $1.60 | $32.00K | 467,156 |
| George F. Tidmarsh Director, 10% owner | Feb 9, 2022 | Buy | +30,000 | $2.55 | $76.50K | 447,156 |
| George F. Tidmarsh Director, 10% owner | Feb 8, 2022 | Buy | +1,000 | $2.54 | $2.54K | 417,156 |
| George F. Tidmarsh Director, 10% owner | Feb 7, 2022 | Buy | +42,100 | $2.61 | $109.88K | 1,523,335 |
| George F. Tidmarsh Director, 10% owner | Feb 7, 2022 | Buy | +42,100 | $2.61 | $109.88K | 1,523,335 |
| George F. Tidmarsh Director, 10% owner | Feb 4, 2022 | Buy | +7,900 | $2.31 | $18.25K | 1,481,235 |
| George F. Tidmarsh Director, 10% owner | Feb 4, 2022 | Buy | +2,000 | $2.45 | $4.90K | 416,156 |
| George F. Tidmarsh Director, 10% owner | Feb 4, 2022 | Buy | +7,900 | $2.31 | $18.25K | 1,481,235 |
| IM Prime Impact Master Fund I. SCA SICAV-RAIF AXA – | Jan 10, 2022 | Other | +1,958,984 | – | – | 1,958,984 |
| Lawrence Feis 10% owner | Jan 10, 2022 | Other | −731,950 | $10.20 | $7.47M | 0 |
| Glazer Capital, Llc 10% owner | Sep 23, 2021 | Sale | −611,541 | $10.08 | $6.16M | 381,106 |
| Glazer Capital, Llc 10% owner | Sep 22, 2021 | Sale | −5 | $10.08 | $50 | 992,647 |
| Glazer Capital, Llc 10% owner | Sep 21, 2021 | Sale | −43,000 | $10.08 | $433.44K | 992,652 |
| Andreas Typaldos Chief Executive Officer, Director, 10% owner | Dec 30, 2020 | Other | −192,962 | – | – | 1,769,538 |
| Sean H. Fitzpatrick Chief Executive Officer, Director, 10% owner | Dec 30, 2020 | Other | −192,962 | – | – | 1,769,538 |
| Glazer Capital, Llc 10% owner | Nov 9, 2020 | Sale | −5,000 | $10.00 | $50.00K | 1,035,652 |
| Glazer Capital, Llc 10% owner | Oct 12, 2020 | Sale | −20 | $10.00 | $200 | 1,040,652 |
| Glazer Capital, Llc 10% owner | Oct 9, 2020 | Sale | −9,328 | $10.00 | $93.28K | 1,040,672 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-63.0%
From 0M shares
Short volume, 20 days
52.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Revelation Biosciences's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| George F Tidmarsh & Courtney Moulds Co-Ttee The Tidmarsh Living Trust U/A Dtd 09/26/2016 Director | Sep 28, 2023 | 1,429 | $986 | Sep 28, 2023 | Open Market Purchase |